|
Blockbuster Patent Expirations and the Future of the Generics Market
Decision Resources - 6/29/2007 - 24 Pages - ID: DECR1539975
URL: http://www.marketresearch.com/product/display.asp?productid=1539975
PDF E-mail From Publisher - $2,250.00
Global Site License Fulfilled by Publisher - $4,500.00
Abstract
Approximately 90 pharmaceuticals achieved blockbuster status in 2006, generating more than $200 billion in
sales—approximately 30% of the global pharmaceutical market. However, in 2007, eight blockbuster brands—
with combined 2006 sales of $13 billion in the United States alone—face patent expiration. Additionally, the
future presents great challenges to the creation of new blockbuster drugs: health care payers are becoming more
cost-conscious, restricting patient access to expensive, blockbuster therapies. And the upcoming expiration of
patents on many current blockbuster drugs will trigger the widespread launch of generics. Finally, the prospective
launch of “biosimilars”—generic versions of biologics—will present unprecedented challenges for stakeholders.
Questions Answered in This Spectrum Report:
- A key patent on simvastatin recently expired in many parts of the world. The loss of protection prompted
payers in some countries to introduce measures promoting the use of generic simvastatin in place of patentprotected
drugs within the same class. How has the loss of simvastatin’s patent protection affected pricing
policies on patent-protected drugs?
- After many years of stagnation, the Japanese generics market is now widely expected to undergo vigorous
growth. Which drug classes do Japanese physicians expect to experience the most robust growth in
generics penetration?
- Despite having the largest population of any country in the European Union, Germany exhibits relatively
modest spending on blockbuster pharmaceuticals. Why are German physicians wary of prescribing these
popular medications?
- As more and more blockbuster products lose patent protection, payers become more and more eager to in-
crease the rate of generics prescribing. What pharmacy benefit management strategies have been gaining
favor among employers? What strategies have been losing support?
Scope:
- U.S. employers’ views on strategies to increase prescription drug benefi t values: the relative
importance of generics substitution, patient compliance, cost-effective products, pharmacy deals,
maximization of rebates.
- Challenges drug manufacturers face in creating new blockbuster drugs: cost-conscious health
care payers; targeted therapies; the launch of generics triggered by upcoming patent expirations.
- Future patent expirations of blockbuster drugs in the seven major markets: total sales fi gures
in each of the seven major markets of blockbuster drugs that lose patent protection in a given year;
patent expiration timetable for 2006 blockbuster drugs; the dominant position of the United States;
France as the largest European market for blockbuster drugs; Germany’s modest spending on blockbuster
drugs; the impact of price cuts in Italy; Spain as the smallest European market for blockbusters;
the generics prescribing culture in the United Kingdom; the absence of blockbuster brands from
the Japanese market.
- Barriers to generics competition: navigating the patent maze; logistical obstacles in the manufacturing
and handling of generics; the unique challenges posed by biologics.
- Payers’ support for generics: U.S. employers’ views of PBMs; new prescription forms, reimbursement
programs, and solutions to supply defi ciencies in Japan.
- Outlook: Major changes expected; growing patient acceptance of generics; increased payer incentives
for generics; increasing physician comfort with generics; the prospective launch of blockbuster
biosimilars.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Schedule of Patent Expirations
- Barriers to Generics Competition
- Payers’ Support for Generics
- United States
- Europe
- Japan
- Outlook and Implications for the Pharmaceutical Industry
- Tables
- 1. Blockbuster Prescription Drugs, 2006
- 2. Patent Expiration Timetable for 2006 Blockbuster Drugs
- 3. Total Sales in the Seven Major Markets of Leading Manufacturers’ Blockbuster Drugs That Will Lose Patent Protection from 2007 to 2017
- 4. U.S. Employers’ Views on Strategies to Increase Prescription Drug Benefit Value, 2005
- Figures
- 1. Total Sales in the United States of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2021
- 2. Total Sales in France of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2019
- 3. Total Sales in Germany of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2019
- 4. Total Sales in Italy of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2019
- 5. Total Sales in Spain of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2019
- 6. Total Sales in the United Kingdom of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2019
- 7. Total Sales in Japan of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2018
- 8. Total Sales in Seven Major Markets of Blockbuster Drugs That Lose Patent Protection in a Given Year from 2007 to 2019
More Details
Companies and Brands Mentioned in This Spectrum Report:
Companies:
- Abbott Laboratories
- Altana
- Amgen
- Astellas Pharma
- AstraZeneca
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Caremark
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Express Scripts
- Forest Laboratories
- Genentech
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Medco
- Merck
- Merck Serono
- Novartis
- Otsuka Pharmaceutical
- Pfi zer
- Procter & Gamble
- Roche
- Sandoz
- Sanofi -Aventis
- Schering-Plough
- Takeda
- TAP Pharmaceutical Products
- Wyeth
Brands:
- Abilify
- Aciphex/Pariet
- Actonel
- Actos
- Ambien/Stilnox/Myslee
- Aranesp
- Aricept
- Arimidex
- Augmentin IR
- Avandia
- Avapro/Aprovel
- Avastin
- Avonex
- Benicar/Olmetec
- Blopress/Atacand
- Casodex
- Celebrex
- CellCept
- Copaxone
- Coreg/Kredex
- Cozaar
- Crestor
- Cymbalta/Xeristar
- Depakote
- Diovan
- Effexor
- Effexor XR
- Eloxatin
- Enbrel
- Epogen
- Evista
- Flixotide/Flovent
- Fluzone/Vaxigrip/Mutagrip
- Fosamax
- Gemzar
- Gleevec/Glivec
- Herceptin
- Humalog
- Humira
- Imigran/Imitrex
- Kaletra
- Lamictal
- Lantus
- Levaquin
- Lexapro
- Lipitor
- Losec/Prilosec
- Lotrel
- Lovenox/Clexane
- Micardis
- NeoRecormon
- Neulasta
- Neupogen
- Nexium
- Norvasc
- Omnitrope
- Paxil CR
- Pegasys
- Plavix/Iscover
- Pravachol
- Prevacid
- Procrit/Eprex
- Prograf
- Protonix
- Pulmicort
- Rebif
- Remicade
- Risperdal
- Rituxan
- Seloken ZOK/Toprol XL
- Seretide/Advair
- Seroquel
- Singulair
- Spiriva
- Symbicort
- Tamifl u
- Taxotere
- Topamax
- TriCor
- Tritace/Delix/Altace
- Truvada
- Valtrex/Zelitrex
- Vytorin/Inergy
- Wellbutrin XL/Wellbutrin XR
- Zetia/Ezetrol
- Zocor
- Zofran
- Zoladex
- Zoloft
- Zometa
- Zyprexa
- Zyrtec/Reactine
|